Biotech MannKind (NASDAQ:56400P706), which is developing the inhalable insulin product Afrezza, released its third-quarter earnings report after the market closed on Thursday. There were several key updates regarding the company's financial situation and cash burn.
In the following video, health-care analysts Max Macaluso and David Williamson discuss these results and a few issues investors need to watch.
David Williamson owns shares of Pfizer. Max Macaluso, Ph.D., and The Motley Fool have no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.